Indian Economy News

Cipla gets USFDA nod for generic acid reflux drug

  • IBEF
  • March 27, 2020

Drug major Cipla received final approval from the US health regulator for generic Esomeprazole for oral suspension used for treatment of gastroesophageal reflux disease.

According to Cipla statement, the company has received final approval for its abbreviated new drug application (ANDA) for Esomeprazole for oral suspension in the strengths of 10mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA).

It added that Cipla is the first company to file for the 10mg strength. This is a generic version of AstraZeneca Pharmaceutical’s Nexium and is used in treatment of gastroesophageal reflux disease, risk reduction of NSAID-associated gastric ulcer, among others, Cipla said.

According to IQVIA, Nexium and its generic equivalents had US sales of around US$ 70 million for the 12 months ended November 2019, it added.

Shares of Cipla were trading at Rs 389 (US$ 5.56) per scrip on the BSE, up 3.27 per cent from the previous close.

 

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.

Partners
Loading...